[go: up one dir, main page]

NO20091545L - Fremgangsmåte for levering av medikament for ben-anabolt protein - Google Patents

Fremgangsmåte for levering av medikament for ben-anabolt protein

Info

Publication number
NO20091545L
NO20091545L NO20091545A NO20091545A NO20091545L NO 20091545 L NO20091545 L NO 20091545L NO 20091545 A NO20091545 A NO 20091545A NO 20091545 A NO20091545 A NO 20091545A NO 20091545 L NO20091545 L NO 20091545L
Authority
NO
Norway
Prior art keywords
protein drug
bone anabolic
delivering bone
anabolic protein
delivering
Prior art date
Application number
NO20091545A
Other languages
English (en)
Other versions
NO344885B1 (no
Inventor
Cecil Richard Lyttle
Michael J Dey
Nathalie Mondoly
Benedicte Rigaud
Bart Henderson
Original Assignee
Ipsen Pharma Sas
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39430237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091545(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ipsen Pharma Sas, Radius Health Inc filed Critical Ipsen Pharma Sas
Publication of NO20091545L publication Critical patent/NO20091545L/no
Publication of NO344885B1 publication Critical patent/NO344885B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
NO20091545A 2006-10-03 2009-04-20 En stabil sammensetning omfattende et benanabolt protein, nemlig en PTHrP-analog, og anvendelser derav NO344885B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84896006P 2006-10-03 2006-10-03
PCT/US2007/021216 WO2008063279A2 (en) 2006-10-03 2007-10-03 A stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof

Publications (2)

Publication Number Publication Date
NO20091545L true NO20091545L (no) 2009-05-27
NO344885B1 NO344885B1 (no) 2020-06-15

Family

ID=39430237

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091545A NO344885B1 (no) 2006-10-03 2009-04-20 En stabil sammensetning omfattende et benanabolt protein, nemlig en PTHrP-analog, og anvendelser derav

Country Status (28)

Country Link
US (1) US8148333B2 (no)
EP (2) EP2073789B8 (no)
JP (1) JP5375611B2 (no)
KR (4) KR20180117738A (no)
CN (2) CN102274492B (no)
AU (1) AU2007322334B2 (no)
BR (2) BRPI0719821B8 (no)
CA (1) CA2664734C (no)
CY (1) CY1119198T1 (no)
DK (2) DK2957278T3 (no)
ES (2) ES2739459T3 (no)
FR (1) FR23C1024I2 (no)
HR (1) HRP20171217T1 (no)
IL (1) IL197926A (no)
LT (1) LT2957278T (no)
LU (1) LUC00309I2 (no)
MX (1) MX2009003569A (no)
NL (1) NL301235I2 (no)
NO (1) NO344885B1 (no)
NZ (1) NZ576682A (no)
PL (1) PL2957278T3 (no)
PT (2) PT2957278T (no)
RS (1) RS56164B1 (no)
RU (1) RU2506070C2 (no)
SG (1) SG175580A1 (no)
SI (1) SI2957278T1 (no)
UA (1) UA98776C2 (no)
WO (1) WO2008063279A2 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5375611B2 (ja) 2006-10-03 2013-12-25 ラジウス ヘルス，インコーポレイテッド 骨同化作用を有するタンパク質のための薬物送達方法
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
SI2568806T1 (sl) 2010-05-12 2016-09-30 Radius Health, Inc. Režimi zdravljenja
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
EP2472328B1 (en) 2010-12-31 2013-06-19 Rohm and Haas Electronic Materials LLC Coating compositions for use with an overcoated photoresist
EP2472329B1 (en) 2010-12-31 2013-06-05 Rohm and Haas Electronic Materials LLC Coating compositions for use with an overcoated photoresist
US20130006217A1 (en) * 2011-04-22 2013-01-03 Gary Hattersley METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES
ES2833277T3 (es) * 2011-06-07 2021-06-14 Asahi Kasei Pharma Corp Preparación liofilizada que contiene PTH de alta pureza y método para producirla
AU2012345768B2 (en) 2011-11-30 2016-05-12 Kindeva Drug Delivery L.P. Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
PT3122426T (pt) 2014-03-28 2023-02-28 Univ Duke Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio
EP4137147A3 (en) * 2015-03-03 2023-04-05 Radius Health, Inc. Uses of abaloparatide in reducing fracture risk
EP3288383A4 (en) 2015-04-29 2019-01-23 Radius Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
CN108025042A (zh) * 2015-07-06 2018-05-11 董正欣 PTHrP类似物的新型制剂
KR101982103B1 (ko) 2015-08-31 2019-05-27 롬 앤드 하스 일렉트로닉 머트어리얼즈 엘엘씨 오버코팅된 포토레지스트와 함께 사용하기 위한 코팅 조성물
SI3359241T1 (sl) * 2015-10-09 2021-11-30 Radius Health, Inc. Formulacije PTHRP-analogov, transdermalni obliži le-teh in uporabe le-teh
AU2017253674B2 (en) 2016-04-18 2021-07-29 Kindeva Drug Delivery L.P. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
HRP20220619T1 (hr) 2016-06-22 2023-02-03 Ellipses Pharma Ltd Postupci za liječenje ar+ raka dojke
CA3045458A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
ES2981967T3 (es) 2017-01-05 2024-10-14 Radius Pharmaceuticals Inc Formas polimórficas de RAD1901-2HCl
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
EP3765488A1 (en) * 2018-03-12 2021-01-20 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of pthrp analogue
EP3796941A4 (en) 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形形態
JOP20210218A1 (ar) 2019-02-12 2023-01-30 Radius Pharmaceuticals Inc عمليات ومركبات
WO2021149012A1 (en) 2020-01-24 2021-07-29 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
WO2023281447A1 (en) 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105772A2 (en) * 2002-06-13 2003-12-24 Beth Israel Deaconess Medical Center, Inc. Analogs of parathyroid hormone and pth-related protein as bone anabolic agents
US20050282749A1 (en) * 2000-09-18 2005-12-22 Henriksen Dennis B Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
KR100291620B1 (ko) 1992-09-29 2001-10-24 추후제출 부갑상선호르몬의활성단편의폐를통한전달방법
WO1995002610A1 (en) 1993-07-13 1995-01-26 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US7410948B2 (en) * 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5969095A (en) * 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
CN1204262A (zh) * 1995-10-17 1999-01-06 曼海姆泊灵格股份公司 稳定的含甲状旁腺激素的药物给药剂型
TW505654B (en) * 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
US6136784A (en) * 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
TR200000649T2 (tr) * 1997-09-09 2000-09-21 F.Hoffmann-La Roche Ag PTHrP analogları kullanılarak kırıkların iyileştirilmesi.
ZA9811127B (en) * 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
SE9801495D0 (sv) 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US20050124537A1 (en) * 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
AU2002359391A1 (en) 2002-11-01 2004-07-29 Amgen, Inc. Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
MXPA06012980A (es) * 2004-05-10 2007-06-12 Nastech Pharm Co Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
JP5375611B2 (ja) 2006-10-03 2013-12-25 ラジウス ヘルス，インコーポレイテッド 骨同化作用を有するタンパク質のための薬物送達方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282749A1 (en) * 2000-09-18 2005-12-22 Henriksen Dennis B Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2003105772A2 (en) * 2002-06-13 2003-12-24 Beth Israel Deaconess Medical Center, Inc. Analogs of parathyroid hormone and pth-related protein as bone anabolic agents

Also Published As

Publication number Publication date
AU2007322334B2 (en) 2011-12-22
RU2009116531A (ru) 2010-11-10
SI2957278T1 (sl) 2017-09-29
DK2073789T3 (da) 2019-08-05
UA98776C2 (ru) 2012-06-25
KR20170067906A (ko) 2017-06-16
RU2506070C2 (ru) 2014-02-10
FR23C1024I1 (fr) 2023-07-21
EP2073789B1 (en) 2019-05-22
DK2957278T3 (en) 2017-07-31
JP5375611B2 (ja) 2013-12-25
EP2073789B8 (en) 2023-02-08
BRPI0722428A2 (pt) 2013-11-26
KR20150020289A (ko) 2015-02-25
MX2009003569A (es) 2009-08-25
CN101578093B (zh) 2011-09-14
CN102274492B (zh) 2014-11-26
IL197926A0 (en) 2011-08-01
BRPI0719821A2 (pt) 2013-05-07
FR23C1024I2 (fr) 2024-06-14
PL2957278T3 (pl) 2017-10-31
CY1119198T1 (el) 2018-02-14
ES2739459T3 (es) 2020-01-31
CA2664734C (en) 2023-08-01
HRP20171217T1 (hr) 2017-10-20
EP2073789A2 (en) 2009-07-01
SG175580A1 (en) 2011-11-28
JP2010505835A (ja) 2010-02-25
KR20180117738A (ko) 2018-10-29
CN101578093A (zh) 2009-11-11
WO2008063279A2 (en) 2008-05-29
BRPI0719821B8 (pt) 2021-05-25
RS56164B1 (sr) 2017-11-30
CN102274492A (zh) 2011-12-14
NO344885B1 (no) 2020-06-15
HK1214181A1 (en) 2016-07-22
PT2957278T (pt) 2017-08-23
KR20090083350A (ko) 2009-08-03
ES2637283T3 (es) 2017-10-11
WO2008063279A3 (en) 2009-06-25
PT2073789T (pt) 2019-07-31
US8148333B2 (en) 2012-04-03
KR101512377B1 (ko) 2015-04-28
AU2007322334A1 (en) 2008-05-29
NZ576682A (en) 2012-08-31
LUC00309I2 (no) 2025-09-22
IL197926A (en) 2014-08-31
EP2957278A1 (en) 2015-12-23
US20100029556A1 (en) 2010-02-04
LT2957278T (lt) 2017-09-11
CA2664734A1 (en) 2008-05-29
EP2957278B1 (en) 2017-05-17
BRPI0719821B1 (pt) 2020-04-14
NL301235I2 (nl) 2023-08-31
WO2008063279A9 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
NO20091545L (no) Fremgangsmåte for levering av medikament for ben-anabolt protein
PT2001312E (pt) Método de preparação de uma bebida de proteínas
DK2023958T4 (da) Farmaceutisk produkt til intraoral levering af nikotin omfattende trometamol som buffermiddel
BRPI0716982A2 (pt) mÉtodo e sistema para infusço controlada de substÂncia terapÊutica
EP2101745A4 (en) ADMINISTRATION OF MEDICINES
IL210883A0 (en) Drug delivery system and method of munufacturing thereof
EP3323405C0 (en) SYSTEM AND METHOD FOR DISPENSING MEDICATION
BRPI0921659A2 (pt) metodo e sistema para formar uma protese dentaria
BRPI0923808A2 (pt) Controle eletrônico de sistema de distribuição de fármaco
BRPI0717482A2 (pt) Sistema para o tratamento de uma alimentação de hidrocarboneto
EP2046213A4 (en) BONE FIXATION SYSTEM AND METHOD OF USE
PT2055308T (pt) Medicamento para promover a regeneração funcional de tecido danificado
EP2132133A4 (en) RELEASE OF PARTICULATE ACTIVE SUBSTANCES
EP2413693A4 (en) SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
BRPI1009418A2 (pt) nanocapsula de proteina, metodo de pdroduzir uma nanocapsula, e metodo de distribuir uma proteina
CY2016053I1 (el) Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
IL211099A0 (en) Formulation for oral administration of proteins
DK3300743T3 (da) Fremgangsmåder til indgivelse af vaccine
DK2506712T3 (da) Morfinanderivater til behandling af lægemiddeloverdosering
BRPI0716790A2 (pt) Método e sistema para produzir uma prótese dentária
EP2429987A4 (en) AMIDE COMPOUND, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
EP2037738A4 (en) feeding method
EP2323587A4 (en) ACTIVE RELEASE IMPLANTS
AP2008004593A0 (en) Antivral drugs for treatment of arenavirus infection
IL196228A0 (en) 4-hydroxythiobenzamide derivatives of drugs

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: IPSEN PHARMA SAS, US